Opensesame signs definitive agreement to acquire Vector

• Transaction Completion: Opensesame Acquisition Corp. has signed a definitive agreement to acquire Vector Science and Therapeutics Inc. via a reverse takeover (RTO).
• New Identity: The combined entity will be renamed "Vector Science and Therapeutics Corp." and trade on the TSX Venture Exchange under ticker "PAIN".
• Exchange Ratio: 10 Opensesame shares/warrants/options are issued for every 1 Vector share/warrant/option.
• Financing: A subscription receipt offering is underway at $0.10 per receipt, targeting $2M-$3M in proceeds held in escrow until closing conditions are met.
• Regulatory Status: Conditional acceptance from the TSX Venture Exchange has been received for the transaction closing.
• Shareholder Approval: Vector shareholders must approve; Opensesame shareholder approval is not required as it is an arm's-length qualifying transaction.

• Execution of Known Plan: The March 17, 2026 news announced the financing and deal structure ($3M offering, 10:1 ratio). The April 14 news confirms the definitive agreement and TSX acceptance. This is a procedural milestone rather than new fundamental information.
• Market Reaction Divergence: Despite positive corporate action, the stock price has declined significantly from its peak of $10.52 (September 2025) to current levels around $4.51. This suggests the market has already priced in skepticism regarding dilution or valuation.
• Dilution Risk: The exchange ratio of 10:1 implies a massive increase in share count. Vector holds ~11.6M shares, which converts to ~116M Opensesame shares alone, excluding existing SPAC shares and warrants. This creates significant overhang risk for existing shareholders.
• Capital Adequacy: The $2M-$3M financing is minimal for a biotechnology entity unless Vector is in very early pre-clinical stages. It does not appear sufficient to fund long-term development without further equity raises, which would dilute holders further.
• Rating Justification: Classified as Routine - Positive because the deal terms were disclosed in March; the April update confirms execution of previously announced plans without introducing new upside catalysts or revenue data.

• Pre-Merger Entity: Opensesame Acquisition Corp. (SPAC vehicle).
• Target Entity: Vector Science and Therapeutics Inc. (Private Biotech/Pharma company).
• Flagship Project: Specific drug candidates or therapeutic pipelines are not detailed in the provided news releases; focus is on corporate structure change.
• Development Stage: Unknown based on provided text, but financing size suggests early-stage development requiring significant capital to advance.